DCOY · XBRL financial data

Decoy Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (DCOY's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	—	—	—	—	—	—	0	—	—	—	228
Research and development	1,036	60*	243	214	137	175*	76	116	62	114*	750	1,304
General and administrative	1,496	911*	1,529	1,253	869	1,313*	1,643	849	833	402*	1,534	1,327
Total operating expenses	2,532	971*	1,772	1,468	1,006	1,489*	1,719	966	895	9,035*	2,284	2,631
Operating income (loss)	(2,532)	(971)*	(1,772)	(1,468)	(1,006)	(1,489)*	(1,719)	(966)	(895)	(9,035)*	(2,284)	(2,631)
Income tax expense (benefit)	—	—	—	—	—	—	—	—	—	year only	—	—
Net income (loss)	(2,443)	(882)*	(1,715)	(1,424)	(972)	(1,464)*	(1,710)	(958)	(873)	(8,978)*	(2,225)	(2,374)
Earnings per share, basic‡ USD per share	(77.96)	—	(49.18)	(35.53)	(11.39)	—	(15.44)	(6.75)	(1.81)	—	(4.18)	(4.46)
Earnings per share, diluted‡ USD per share	(77.96)	—	(49.18)	(35.53)	(11.39)	—	(15.44)	(6.75)	(1.81)	—	(4.18)	(4.46)
Weighted average shares, basic‡ thousands of shares	31	—	35	40	86	—	111	142	482	—	532	532
Weighted average shares, diluted‡ thousands of shares	31	—	35	40	86	—	111	142	482	—	532	532

‡ Per-share figures and share counts are adjusted for the 1-for-8 stock split (June 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-14.992503748125937 stock split (August 2025); filings made before it reported them unadjusted.
† Share count changed about 1/11 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (DCOY's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	7,581	5,900	4,373	3,273	3,284	2,435	1,798	795	4,810	10,710	7,821	8,289
Prepaid and other current assets	743	620	457	241	539	553	507	565	1,255	275	537	284
Total current assets	8,324	6,520	4,830	3,514	3,823	2,988	2,305	1,360	6,065	10,985	8,358	8,573
Property and equipment, net	—	—	—	—	—	0	—	—	—	41	36	399
Total assets	8,404	6,587	4,884	3,554	3,859	3,023	2,339	1,393	6,097	11,057	8,423	9,001
Accounts payable	1,089	603	714	643	166	937	1,471	1,482	1,104	941	936	1,327
Total current liabilities	—	—	—	—	—	1,511	—	—	—	5,168	4,546	4,680
Total liabilities	2,321	1,299	1,234	1,178	935	1,511	2,278	2,223	1,849	5,168	4,546	4,680
Accumulated deficit	(75,466)	(76,348)	(78,063)	(79,488)	(80,460)	(81,924)	(83,633)	(84,591)	(85,464)	(94,442)	(96,667)	(99,041)
Total stockholders' equity	6,084	5,287	3,650	2,375	2,925	1,512	62	(830)	4,248	5,889	3,877	4,321
Total liabilities and equity	8,404	6,587	4,884	3,554	3,859	3,023	2,339	1,393	6,097	11,057	8,423	9,001
Common shares outstanding (cover page)‡ thousands of shares	33	36	40	96	96	116	142	510	5,862	532	532	655

‡ Per-share figures and share counts are adjusted for the 1-for-8 stock split (June 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-14.992503748125937 stock split (August 2025); filings made before it reported them unadjusted.
† Share count changed about 1/11 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (DCOY's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,443)	(882)*	(1,715)	(1,424)	(972)	(1,464)*	(1,710)	(958)	(873)	(8,978)*	(2,225)	(2,374)
Stock-based compensation	113*	85*	78	85*	60*	51*	34	23*	23*	140*	213	206*
Depreciation and amortization	6*	1*	1	1*	1*	1*	1	1*	1*	4*	6	14*
Net cash from operating activities	(3,749)*	(1,511)*	(1,354)	(1,072)*	(1,357)*	(743)*	(1,182)	(862)*	(1,647)*	(1,136)*	(2,889)	(2,652)*
Net cash from investing activities	0*	0*	—	—	—	0*	—	—	(200)*	965*	—	—
Net cash from financing activities	(212)*	(169)*	(173)	(28)*	1,368*	(107)*	546	(141)*	5,861*	6,072*	0	3,163*
Net change in cash	(3,961)*	(1,681)*	(1,527)	(1,100)*	11*	(850)*	(636)	(1,003)*	4,015*	5,900*	(2,889)	469*

† Share count changed about 1/11 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Decoy Therapeutics	8,289	228	(2,652)*	655,185	3.1 quarters	Q2 FY26 10-QJun 30, 2026
Scorpius Holdings	582	not reported	(2,917)*	61.1M	0.2 quarters	Q3 FY25 10-QSep 30, 2025
Nomad Power Solutions	12,670	not reported	(1,612)*	16.1M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Clearside Biomedical	6,801	201	(5,480)*	5.2M	1.2 quarters	Q3 FY25 10-QSep 30, 2025
ProtoKinetix	1.1	not reported	0.6*	411.6M	—	Q4 FY25 10-KDec 31, 2025
Galera Therapeutics	5,500	not reported	(875)	160.4M	6.3 quarters	Q1 FY26 10-QMar 31, 2026
Cannapharmarx	0.6	276	(127)*	708.7M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Propanc Biopharma	832	not reported	(1,602)*	6.3M	0.5 quarters	Q4 FY26 10-KJun 30, 2026
Agentix	0	not reported	(26)	40.1M	0.0 quarters	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.